Amifostine does not protect against the ototoxicity of high‐dose cisplatin combined with etoposide and bleomycin in pediatric germ‐cell tumors
Cancer2005Vol. 104(4), pp. 841–847
Citations Over TimeTop 10% of 2005 papers
Neyssa Marina, Kay W. Chang, Marcio H. Malogolowkin, Wendy B. London, A. Lindsay Frazier, Richard B. Womer, Frederick J. Rescorla, Deborah F. Billmire, Mary M. Davis, Elizabeth J. Perlman, Roger Giller, Stephen J. Lauer, Thomas A. Olson
Abstract
Amifostine did not protect against HDPEB-associated ototoxicity.
Related Papers
- Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.(2012)
- → Assessment of the Protective Effects of Amifostine against Cisplatin-Induced Toxicity(2003)22 cited
- → Bleomycin-induced pulmonary nodules: A variant of bleomycin pulmonary toxicity(1987)16 cited
- → Administering amifostine prior to and during cisplatin infusions can significantly reduce the risk of severe ototoxicity(2008)
- → Administering amifostine prior to and during cisplatin infusions can significantly reduce the risk of severe ototoxicity(2008)